ZBH
Zimmer Biomet Holdings, Inc.

Healthcare · Medical Devices · valued as of 2026-11-03 · statements 2025-12-31

Average Intrinsic Value

$12.89B

Market Cap

$16.81B

Margin of Safety

-30.4%

Intrinsic / Market Ratio

0.77

Projections, not exact values. Intrinsic Values are projected from each company's past reports. They show which stocks look cheap compared with the others, not exactly what a stock is worth.

How Each Value Is Built

The screener's three formulas on the reported figures. Each card reads the same way: the value as a sum of numbered terms, each term's calculation opened under it, from the reported figures to the value. The list ranks companies by their plain average over the market cap.

EPV + Growth

13.98B USD

what the normal year's earnings are worth for ever, plus growth that pays

Profit

12.86B USD

15 years of cash the shareholders can take out, and the equity left at year 15

FCFF

11.84B USD

15 years of cash for shareholders and lenders, less what is owed

Intrinsic Value

12.89B USD

the plain average of the three, uncapped, as the screener averages them

Intrinsic Value

12.89B USD

from the sum above

Market Cap

16.81B USD

the price on the date above times the shares

Intrinsic Value ÷ Market Cap

0.77×

the ratio the screener ranks by; Margin of Safety -30.4% (1 − Market Cap ÷ Intrinsic Value)

Each card below builds one of the three values from the reported years.

Earnings power value plus growth: 13.98B USD
What the normal year's operating profit after tax is worth if it lasts for ever, plus what the new investment adds beyond its cost, less the net debt that comes before the shareholders (or plus the net cash).
①EPV (earnings power value)21.06B USD
−②Net Debt Today7.08B USD
+③Growth Value0 USD
=Value13.98B USD

EPV of the Operations (NOPAT over WACC)

21.06B USD

Net debt today

-7.08B USD

Growth Value

0 USD

Value

13.98B USD

①EPV (earnings power value)

21.06B USD

②Net Debt Today

7.08B USD

③Growth Value

0 USD

Market value

Market Cap16.81B USD

The price on the date above times the shares.

Value vs market

Margin of Safety-20.3%

1 minus the market cap as a share of the value.

Profit value: today's value of the shareholders' equity, from the cash it can pay them (FCFE): 12.86B USD
Fifteen years of free cash flow to equity (FCFE), each brought to today at the cost of equity, plus the equity at year 15 brought to today.
①Present Value of the 15 Years of FCFE7.16B USD
+②Equity at Year 15, Today5.70B USD
=Value12.86B USD
FCFE: the net income left for the shareholders once the business keeps what next year's growth needsEquity reinvestment: the part of the year's net income kept in the business to grow the next year; below zero, capital the business releases to the shareholdersPresent value of the FCFEColoured bars show the FCFE, grey bars the equity reinvestment. With a positive equity reinvestment the two stacked are the year's normalized income; with a negative one the grey is below zero, capital the business releases, and the normalized income is the FCFE plus that negative amount. Shaded, years 6 to 10: the growth rising to its long-run rate and the ROE on new investment falling to the cost of equity. Axes linear.

①Present Value of the 15 Years of FCFE

7.16B USD

②Equity at Year 15, Today

5.70B USD

Market value

Market Cap16.81B USD

The price on the date above times the shares.

Value vs market

Margin of Safety-30.7%

1 minus the market cap as a share of the value.

FCFF value: today's value of the shareholders' equity, from the cash the firm can pay its shareholders and lenders (FCFF): 11.84B USD
Fifteen years of free cash flow to the firm (FCFF), each brought to today at the WACC, plus the invested capital at year 15 brought to today, less the net debt today (or plus the net cash).
①Present Value of the 15 Years of FCFF10.22B USD
+②Invested Capital at Year 15, Today8.69B USD
−③Net Debt Today7.08B USD
=Value11.84B USD
FCFF: the NOPAT left for the shareholders and the lenders once the business reinvests what next year's growth needsReinvestment: the part of the year's NOPAT put back into the business to grow the next year; below zero, capital the business releasesPresent value of the FCFFColoured bars show the FCFF, grey bars the reinvestment. With a positive reinvestment the two stacked are the year's NOPAT; with a negative one the grey is below zero, capital the business releases, and the NOPAT is the FCFF plus that negative amount. Shaded, years 6 to 10: the growth rising to its long-run rate and the ROIC on new investment falling to the WACC. Axes linear.

①Present Value of the 15 Years of FCFF

10.22B USD

②Invested Capital at Year 15, Today

8.69B USD

③Net Debt Today

7.08B USD

Market value

Market Cap16.81B USD

The price on the date above times the shares.

Value vs market

Margin of Safety-42.1%

1 minus the market cap as a share of the value.

The Rates and the Capital the Values Read

The WACC and the cost of equity each value is discounted at, the book value and the net debt each starts from, and the seven quality metrics, from the same run.

WACC: 6.09%
Cost of Equity =Risk-Free Rate 4.50%+Beta 0.47×Market Risk Premium 6.00%= 7.33%

The yearly return the shareholders require for the risk they carry; it is the rate that brings their future cash to today.

Tax Rate for WACC =Tax Provision 125.83M USDPretax Income 831.63M USD= 15.13%

The tax the interest saves.

Interest Expense =EBIT 1.12B USD−Pretax Income 831.63M USD= 293.09M USD

The interest the company paid: EBIT is the profit before tax plus the interest.

Cost of Debt =Interest Expense 293.09M USDTotal Debt 7.49B USD×(1 − Tax Rate for WACC 15.13%)= 3.32%

What the lenders are paid a year after the tax the interest saves.

Debt Weight =Total Debt 7.49B USDMarket Cap + Total Debt 16.81B USD + 7.49B USD= 30.81%

The part of the capital the lenders put in, at market value.

WACC =Equity Weight 69.19%×Cost of Equity 7.33%+Debt Weight 30.81%×Cost of Debt 3.32%= 6.09%

Weighted average cost of capital: the yearly return the shareholders and the lenders together require, weighted by what each puts in; the rate that brings the firm's future cash to today.

Book value and net debt today
Both from the balance sheet of the newest quarter, 2026-06-30.

Total Assets 22.82B USD − Total Liabilities 10.18B USD = Book Value Today 12.65B USD

Total Debt 7.49B USD − Cash and Short-Term Investments 410.41M USD = Net Debt Today 7.08B USD

The book value is what Profit starts from and what stands when a projection is not made; the book value plus the net debt is what FCFF starts from; the net debt comes off Greenwald's and FCFF's values before the shareholders.

Quality metrics
Read beside the value, never a condition for it: every company is valued, and a filter in the list is the reader's choice.
MetricFrom
Share dilutionShares Today ÷ Shares Two Years Back − 1-7.3%at most 5%passes190,562,482 / 205,600,000
Accrual quality(Operating Cash Flow − Net Income) ÷ Total Assets4.4%at least -10.0%passes(1.70B USD − 705.81M USD) ÷ 22.82B USD
Price to bookMarket Cap ÷ Book Value Today1.33×at most 3×passes16.81B USD ÷ 12.65B USD
Operating marginOperating Income ÷ Revenue16.5%above 10.0%passes1.36B USD ÷ 8.24B USD
Revenue growthRevenue ÷ Revenue a Year Before − 17.2%above 10.0%does not pass8.24B USD / 7.69B USD
Net cash(Cash − Total Debt) ÷ Market Cap-42.1%above -30%does not pass(410.41M USD − 7.49B USD) ÷ 16.81B USD
Operating efficiencyOperating Income ÷ Gross Profit23.6%above 25.0%does not pass1.36B USD ÷ 5.74B USD

Market Data

The provider's ratios and the analysts' consensus beside the argument; none of them enters a value.

Share price

88 USD

Enterprise value

23.97B USD

the provider's own figure

EV / EBITDA

9.48×

Price / book

1.33×

the provider's book

Price / earnings

21.37×

Return on equity

6.4%

the provider's, not the engine's

Profit margin

9.5%

Revenue growth

4.8%

Analyst target, mean

108 USD

Analysts

21

opinions in the consensus

Financial Statements

The income statement, the balance sheet and the cash flow the screener holds, year by year, in USD.

The annual lines the screener holds today, in USD at each period's rate; the figures this valuation read are in its calculation above.
USD2022202320242025
Income statement

Revenue

6.95B7.40B7.69B8.24B

Gross profit

4.93B5.32B5.49B5.74B

Operating income

1.19B1.45B1.53B1.36B

EBITDA

operating income before depreciation and amortisation

1.50B2.22B2.25B2.22B

Pretax income

403.90M1.07B1.04B831.63M

Net income

231.63M1.03B904.70M705.81M

Normalized income

net income without one-off items, as the data provider prints it; Profit's line when printed

648.32M1.19B1.12B925.07M

R&D

406.41M459.16M437.84M458.96M
Balance sheet, year end

Total assets

21.09B21.52B21.39B23.11B

Total liabilities

9.05B9.02B8.90B10.40B

Shareholders' equity

the equity the parent's shareholders own, as printed, without minority interest; the book value the values read is total assets less total liabilities, in Book Value and Net Debt above

12.03B12.49B12.48B12.71B

Total debt

5.70B5.77B6.21B7.53B

Cash and equivalents

376.08M416.22M526.03M592.49M

Net PP&E

fixed assets after depreciation

1.87B2.06B2.05B2.21B

Working capital

current assets less current liabilities

2.07B1.75B2.22B2.54B
Cash flow

Operating cash flow

1.29B1.58B1.50B1.70B

Capital expenditure

paid out, so below zero

-217.82M-394.89M-357.16M-277.18M

Depreciation and amortisation

927.33M952.65M997.30M1.09B

Free cash flow

operating cash flow plus capital expenditure

1.07B1.19B1.14B1.42B